Literature DB >> 29588801

Evidence for Benefit of Percutaneous Coronary Intervention for Chronically Occluded Coronary Arteries (CTO) - Clinical and Health Economic Outcomes.

John Rawlins1, James Wilkinson1, Nick Curzen1,2.   

Abstract

Percutaneous revascularisation of a coronary chronic total occlusion (CTO) remains one of the technical frontiers of interventional cardiology. CTOs are common, and yet intervention is only attempted in 10 % of cases. CTO procedures are perceived to be technically challenging, lengthy, associated with significant risk and have only limited data to support the practise. Recent technical advances have dramatically increased the success rate, shortened procedural time and improved clinical outcomes. The aim of this article is to critically examine the data that supports CTO intervention, including specifically an appraisal of procedural safety, benefit and overall cost effectiveness.

Entities:  

Keywords:  Chronic total occlusions (CTO); benefits; economic outcomes

Year:  2014        PMID： 29588801      PMCID： PMC5808720          DOI： 10.15420/icr.2014.9.3.190

Source DB:  PubMed          Journal:  Interv Cardiol        ISSN： 1756-1485


  26 in total

Review 1.  A percutaneous treatment algorithm for crossing coronary chronic total occlusions.

Authors:  Emmanouil S Brilakis; J Aaron Grantham; Stéphane Rinfret; R Michael Wyman; M Nicholas Burke; Dimitri Karmpaliotis; Nicholas Lembo; Ashish Pershad; David E Kandzari; Christopher E Buller; Tony DeMartini; William L Lombardi; Craig A Thompson
Journal:  JACC Cardiovasc Interv       Date:  2012-04       Impact factor: 11.195

Review 2.  Recanalisation of chronic total coronary occlusions: 2012 consensus document from the EuroCTO club.

Authors:  Georgios Sianos; Gerald S Werner; Alfredo R Galassi; Michail I Papafaklis; Javier Escaned; David Hildick-Smith; Evald Høj Christiansen; Anthony Gershlick; Mauro Carlino; Angelos Karlas; Nikolaos V Konstantinidis; Salvatore D Tomasello; Carlo Di Mario; Nicolaus Reifart
Journal:  EuroIntervention       Date:  2012-05-15       Impact factor: 6.534

Review 3.  Chronic total occlusion angioplasty in the United States.

Authors:  J Aaron Grantham; Steven P Marso; John Spertus; John House; David R Holmes; Barry D Rutherford
Journal:  JACC Cardiovasc Interv       Date:  2009-06       Impact factor: 11.195

4.  Multicentre experience with the BridgePoint devices to facilitate recanalisation of chronic total coronary occlusions through controlled subintimal re-entry.

Authors:  Gerald S Werner; Joachim Schofer; Horst Sievert; Chad Kugler; Nicolaus J Reifart
Journal:  EuroIntervention       Date:  2011-06       Impact factor: 6.534

5.  Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry.

Authors:  Eric D Peterson; David Dai; Elizabeth R DeLong; J Matthew Brennan; Mandeep Singh; Sunil V Rao; Richard E Shaw; Matthew T Roe; Kalon K L Ho; Lloyd W Klein; Ronald J Krone; William S Weintraub; Ralph G Brindis; John S Rumsfeld; John A Spertus
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

6.  Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial.

Authors:  J Aaron Grantham; Philip G Jones; Louis Cannon; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-04-13

7.  Changes in myocardial ischemic burden following percutaneous coronary intervention of chronic total occlusions.

Authors:  David M Safley; Sindhu Koshy; J Aaron Grantham; Kevin A Bybee; John A House; Kevin F Kennedy; Barry D Rutherford
Journal:  Catheter Cardiovasc Interv       Date:  2011-03-16       Impact factor: 2.692

8.  Evaluation of the effect of a concurrent chronic total occlusion on long-term mortality and left ventricular function in patients after primary percutaneous coronary intervention.

Authors:  Bimmer E P M Claessen; René J van der Schaaf; Niels J Verouden; Nienke K Stegenga; Annemarie E Engstrom; Krischan D Sjauw; Wouter J Kikkert; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan G P Tijssen; Jan J Piek; José P S Henriques
Journal:  JACC Cardiovasc Interv       Date:  2009-11       Impact factor: 11.195

9.  Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions.

Authors:  Sharon W Kirschbaum; Timo Baks; Martin van den Ent; George Sianos; Gabriel P Krestin; Patrick W Serruys; Pim J de Feyter; Robert-Jan M van Geuns
Journal:  Am J Cardiol       Date:  2007-12-03       Impact factor: 2.778

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690
View more
  2 in total

Review 1.  Factors Impacting Stent Thrombosis in Patients With Percutaneous Coronary Intervention and Coronary Stenting: A Systematic Review and Meta-Analysis.

Authors:  Nso Nso; Mahmoud Nassar; Milana Zirkiyeva; Yolanda Mbome; Anthony Lyonga Ngonge; Solomon O Badejoko; Shahzad Akbar; Atika Azhar; Sofia Lakhdar; Laura M Guzman Perez; Yousef Abdalazeem; Vincent Rizzo; Most Munira
Journal:  Cureus       Date:  2022-04-09

2.  Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model.

Authors:  Mohammad Sheibani; Hedyeh Faghir-Ghanesefat; Saman Dehpour; Hedieh Keshavarz-Bahaghighat; Mohammad Reza Sepand; Mohammad Hossein Ghahremani; Yaser Azizi; Nastaran Rahimi; Ahmad Reza Dehpour
Journal:  Inflammopharmacology       Date:  2019-03-30       Impact factor: 5.093
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.